| Sign In to gain access to subscriptions and/or personal tools. |
Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodiesDepartment of Internal Medicine, Huriez Hospital, University Hospital, University of Lille 2, Lille, France; Research Department on Lipoproteins and Atherosclerosis, INSERM U325. Pasteur Institute and University of Lille 2, Lille, France
Research Department on Lipoproteins and Atherosclerosis, INSERM U325. Pasteur Institute and University of Lille 2, Lille, France
Department of Internal Medicine, Huriez Hospital, University Hospital, University of Lille 2, Lille, France
Research Department on Lipoproteins and Atherosclerosis, INSERM U325. Pasteur Institute and University of Lille 2, Lille, France
Department of Internal Medicine, Huriez Hospital, University Hospital, University of Lille 2, Lille, France
Déines et l'Athérosclérose, INSERM U325, Institut Pasteur, 1 rue du Professeur Calmette, BP 245, 59019, Lille, France. Tel: (/33) 3 20 87 78 86; Fax: (/33) 3 20 87 73 60; Patrick.Duriez{at}pastcur-lille.fr It has been reported that paraoxonase 1 (PON1) activity inhibits low-density lipoprotein (LDL) oxidation and modulates the risk of coronary heart disease. This study shows that autoantibodies (IgG) directed against modified LDL were increased in 71 patients positive for anticardiolipin antibodies. In a representative subgroup of these patients (n 36) PON1 activity was dramatically decreased and the prevalence of the RR genotype of this enzyme tended to be increased in patients who had developed arterial thrombosis. This study suggests that PON1 abnormalities play a role in the antiphospholipid syndrome.
Key Words: paraoxonase 1 anticardiolipin antibodies oxidized-LDL
Lupus, Vol. 9, No. 4,
299-300 (2000) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

